Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 1, 2011, Pages 339-344

  Clement, Christian ^a   Capriotti, Joseph A ^b,c   Kumar, Manish ^d   Hobden, Jeffery A ^e   Foster, Timothy P ^e   Bhattacharjee, Partha S ^a,f   Thompson, Hilary W ^a,e,g,h   Mahmud, Rashed ^a   Liang, Bo ^c   Hill, James M ^a,e,h  

^a Departments of Ophthalmology Department   (United States)

^b Ocean Ophthalmology Group   (United States)

^c CLS Pharmaceuticals Inc   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Department of Microbiology Immunology and Parasitology ^*  (United States)

^f XAVIER UNIVERSITY OF LOUISIANA   (United States)

^g Tulane School of Public Health   (United States)

^h LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BALANCED SALT SOLUTION; CIDOFOVIR; DEXAMETHASONE PLUS POVIDONE IODINE; DEXAMETHASONE PLUS TOBRAMYCIN; FST 100; UNCLASSIFIED DRUG; CYTOSINE; DEXAMETHASONE; DRUG; DRUG DERIVATIVE; EYE DROPS; PHOSPHONIC ACID DERIVATIVE; POVIDONE IODINE; TOBRAMYCIN; TOPICAL ANTIINFECTIVE AGENT;

ADENOVIRUS 5; ADENOVIRUS INFECTION; ADENOVIRUS KERATOCONJUNCTIVITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BLEPHARITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; EPIPHORA; EYE TOXICITY; HISTOPATHOLOGY; KERATOCONJUNCTIVITIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PUS; RABBIT; RANDOMIZED CONTROLLED TRIAL; SCLERA DISEASE; SYMPTOM; VIRUS LOAD; VIRUS PLAQUE; VIRUS SHEDDING; VIRUS TITRATION; ADENOVIRUS; ANIMAL; COMPARATIVE STUDY; CONJUNCTIVA; DISEASE MODEL; DRUG COMBINATION; GROWTH, DEVELOPMENT AND AGING; TREATMENT OUTCOME; VIRAL CONJUNCTIVITIS; VIROLOGY; VIRUS CULTURE;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; CONJUNCTIVA; CONJUNCTIVITIS, VIRAL; CYTOSINE; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; PHOSPHONIC ACIDS; PLAQUE ASSAY; POVIDONE-IODINE; RABBITS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 79952270499     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5944     Document Type: Article

References (50)

1. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, et al. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol. 1999;37:3940-3945.
2. Schrauder A, Altmann D, Laude G, et al. Epidemic conjunctivitis in Germany. 2004. Eur Surveill. 2006;11:185-187.
3. Asencio-Durán M, Romero-Martín R, García-Martínez JR, et al. Nosocomial outbreak of epidemic keratoconjunctivitis in a neonatal intensive care unit (in Spanish). Arch Soc Esp Oftalmol. 2007;82:73-79.
4. Kumar NL, Black D, McClellan K. Daytime presentations to a metropolitan ophthalmic emergency department. Clin Exp Ophthalmol. 2005;33:586-592.
5. Ford E, Nelson KE, Warren D. Epidemiology of epidemic keratoconjunctivitis. Epidemiol Rev. 1987;9:244-261.
6. Teuchner B, Nagl M, Schidlbauer A, et al. Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis: a doubleblind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther. 2005;21:157-165.
7. Romanowski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci. 2000;41:460-463.
8. Clinicaltrials.gov web site. An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis. Identifier: NCT00901693. Available at: http://clinicaltrials.gov/ct2/results?termNCT00901693. Accessed May 24, 2010.
9. Clinicaltrials.gov web site. An FST-201 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis. Identifier: NCT00941486. Available at: http://clinicaltrials.gov/ct2/results?termNCT00941486. Accessed May 24, 2010.
10. Epstein SP, Pashinsky YY, Gershon D, et al. Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model. BMC Ophthalmol. 2006;6:22.
11. Hartley C, Hartley M, Pardoe I, Knight A. Ionic contra-viral therapy (ICVT); a new approach to the treatment of DNA virus infections. Arch Virol. 2006;151:2495-2501.
12. De Oliveira CB, Stevenson D, LaBree L, McDonnell PJ, Trousdale MD. Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res. 1996;31:165-172.
13. Gordon YJ, Romanowski EG, Araullo-Cruz TP, et al. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic-GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res. 1991;16:11-16.
14. Mentel R, Kinder M, Wegner U, von Janta-Lipinski M, Matthes E. Inhibitory activity of 3'-fluoro-2' deoxythymidine and related nucleoside analogues against adenovirus in vitro. Antiviral Res. 1997;34:113-119.
15. Mentel R, Wegner U. Evaluation of the efficacy of 2',3'-dideoxycytidine against adenovirus infection in a mouse pneumonia model. Antiviral Res. 2000;47:79-87.
16. Hillenkamp J, Reinhard T, Ross RS, et al. The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology. 2002;109:845-850.
17. Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 2001;52:275-280.
18. Uchio E, Fuchigami A, Kadonosono K, et al. Antiadenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2007;245:1319-1325.
19. Romanowski EG, Yates KA, Gordon YJ. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections. Invest Ophthalmol Vis Sci. 2009;50:5295-5299.
20. Inoue H, Sonoda K-H, Ishikawa M, Kadonosono K, Uchio E. Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo. Ophthalmologica. 2009;223:233-238.
21. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:1290-1297.
22. Gavin PJ, Katz BZ. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics. 2002;110:e9.
23. Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antiviral Ther. 2005;10:225-229.
24. O'Brien TP, Jeng BH, McDonald M, Raizman MB. Acute conjunctivitis: truth and misconceptions. Curr Med Res Opin. 2009;25:1953-1961.
25. Pelletier JS, Stewart K, Trattler W, et al. A combination povidoneiodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009;26:776-783.
26. Awan MA, Agarwal PK, Watson DG, McGhee CNJ, Dutton GN. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93:708-713.
27. Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology. 2002;109:1187-1191.
28. Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects on loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers (published correction appears in Cornea. 2008;37:389). Cornea. 2008;27:50-55.
29. Mohan N, Gupta V, Tandon R, Gupta SK, Vajpayee RB. Topical ciprofloxacin-dexamethasone combination therapy after cataract surgery: randomized controlled clinical trial. J Cataract Refract Surg. 2001;27:1975-1978.
30. Romanowski EG, Roba LA, Wiley L, Araullo-Cruz T, Gordon YJ. The effects of corticosteroids of adenoviral replication. Arch Ophthalmol. 1996;114:581-585.
31. Kadam SP. Application of betadine (povidone iodine) to infected corneal ulcer. Indian J Ophthalmol. 1987;35(5-6):135-136.
32. Isenberg SJ, Apt L, Valenton M, et al. A controlled trial of povidoneiodine to treat infectious conjunctivitis in children. Am J Ophthalmol. 2002;134:681-688.
33. Safar A, Dellimore MC. The effect of povidone iodine flush versus drops on conjunctival colonization before intravitreal injections. Int Ophthalmol. 2007;27:307-312.
34. Ferguson AW, Scott JA, McGavigan J, et al. Comparison of 5% povidone-iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomized double blind study. Br J Ophthalmol. 2003;87:163-167.
35. Benevento WJ, Murray P, Reed CA, Pepose JS. The sensitivity of Neisseria gonorrhoeae, Chlamydia trachomatis, and herpes simplex type II to disinfection with povidone-iodine. Am J Ophthalmol. 1990;109:329-333.
36. Isenberg SJ, Apt L. The ocular application of povidone-iodine. Community Eye Health. 2003;16:30-31.
37. Melki SA, Safar A, Yaghouti F, et al. Effect of topical povidoneiodine versus topical ofloxacin on experimental Staphylococcus keratitis. Graefes Arch Clin Exp Ophthalmol. 2000;238:459-462.
38. Bhagwat D, Oshlack B. Stabilized PVP-I solutions. United States Patent 5126127. June 30, 1992. Available at: www.freepatentsonline.com/5126127.html. Accessed May 24, 2010.
39. Berkelman RL, Holland BW, Anderson RL. Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol. 1982;15:635-639.
40. Jiang J, Wu M, Shen T. The toxic effects of different concentrations of povidone iodine on the rabbit's cornea. Cutan Ocul Toxicol. 2009;28:119-124.
41. Lipsitz SR, Kim K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Stat Med. 1994;13:1149-1163.
42. Neter J, Wasserman W, Kutner MH. Applied Linear Statistical Models. 3rd ed. Homewood, IL: Irwin; 1990.
43. Romanowski EG, Yates KA, Gordon YJ. Topical corticosteroids of limited potency promote adenovirus replication in the Ad5/NZW rabbit ocular model. Cornea. 2002;21:289-291.
44. Romanowski EG, Araullo-Cruz T, Gordon YJ. Multiple adenoviral serotypes demonstrate host range extension in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci. 1998;39:532-536.
45. Kaneko H, Mori S, Suzuki O, et al. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Antiviral Res. 2004;61:63-66.
46. Trousdale MD, Nóbrega R, Wood RL, et al. Studies of adenovirusinduced eye disease in the rabbit model. Invest Ophthalmol Vis Sci. 1995;36:2740-2748.
47. Tsai JC, Garlinghouse G, McDonnell PJ, Trousdale MD. An experimental animal model of adenovirus-induced ocular disease: the cotton rat. Arch Ophthalmol. 1992;110:1167-1170.
48. Trousdale MD, Goldschmidt PL, Nóbrega R. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea. 1994;13:435-439.
49. Gordon YJ, Romanowski EG, Araullo-Cruz T. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci. 1994;35:4135-4143.
50. Romanowski EG, Araullo-Cruz T, Gordon YJ. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci. 1997;38:253-257.